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Summary.-Eleven patients with measurable subcutaneous or pulmonary meta-
stases were selected for a study of the effectiveness of the radiosensitizer misonida-
zole (MIS). Evaluable data were obtained in 6 patients and radiosensitization demon-
strated in 5. Patients were irradiated either before or after MIS, and each patient
acted as his own control. Response to treatment in 5 cases was assessed in terms of
growth delay, and radiation doses were selected in expectation of enhancement
ratios of 1-2 to 1.5. In I case evidence of sensitization was obtained from differential
tumour clearance from 2 areas of skin irradiated before or after MIS. Results in4/5 growth-delay studies indicated enhancement ratios ranging from 1-1 to >1-5. An
enhancement ratio of 1-3 was measured in a case of squamous carcinoma treated by a
10-fraction course of irradiation. Evidence of sensitization was obtained in breast
carcinoma, osteosarcoma, leiomyosarcoma, prostatic carcinoma and synoviosar-
coma. The results of this study support the view that MIS may improve the radio-
therapeutic management of a wide range of tumours, although more extensive data
are required to identify those categories of disease in which greatest benefit will be
obtained, and to indicate the optimum radiation schedule.
ALTHOUGH animal experiments have
shown that misonidazole (MIS) is an
effective sensitizer of hypoxic cells, and
that its use improves the local cure rate of
a wide range of experimental tumours
(Denekamp & Fowler, 1978) it is likely to
be several yearsbefore clinicaltrials in man
can confirm or refute its value in clinical
practice. For this reason it isimportant to
attempt to derive quantitative informa-
tion from the careful assessment of indi-
vidualpatients in whom measurable meta-
stases can be irradiated before or after
MIS using graded doses of radiation and
with the patient acting as his own control.
In these patients metastases can be
assessed growing in the same conditions
and tumour response measured in terms
of volume growth delay. This technique has been used to a limited extent to in-
vestigate MIS (Thomlinson et al., 1976;
Dawes et al., 1978). In the study by
Thomlinson and his colleagues, evidence
of radiosensitization was obtained in a
patient with multiple subcutaneous de-
posits from a carcinoma of the cervix,
who received large single doses of irradia-
tion before and after MIS. In the present
study we have adopted this approach in a
group of 6 patients, with a range of
histologies, who were treated with a range of radiation doses and, in I case, fraction-
ated irradiation.
PATIENTS AND METHODS
Patients
Patients requiring palliative irradiation,
in whom there were measurable metastases,
were eligible for study. In spite of the large number ofpatientspresentingwith metastatic
disease, few were considered suitable. Reasons
for exclusion included the impossibility of
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performing accurate tuiiioui- measureiiients,
the administration of concurrent or planned
systemictherapy, or the difficulties ofregular
follo'ki%up examinations due togeneraldebility
or geographic location. Patients were not
included if it was felt that their probable
survival time was insufficient to permit
observation during the regression and re-
growth phases of tumour gro,,Ath.
Of II patients who -,Nere selected for treat-
ment and received radiation, either preceded
or followed by MIS to a number of measur-
able secondarydeposits, onlv 6 are evaluable.
Of the remainder. 3 died during the early
phase of the study and in 2 patients tumour
regression could not be assessed adequately,
because the treatment response made it
impossible to measure the tumouraccurately.
Study details
Radiothei-apy.-In all the cases studied,
local radiotherapy plus MIS was the only
anti-tumour treatment during the period of
the study. The patients had either failed
to respond to previous chemotherapy or
hormone therapy, or -%N-ere unsuitable for
treatment with cytotoxic drugs. All patients
were studied at least one month after cessa-
tion of any previous anti-tumour therapy.
Cutaneous or subcutaneous lesions were
treated by superficial X-rav therapy (150
kV) or short-distance cobalt therapy, to
ensure even distribution of dose throughout
the treated lesion. Lung metastases were
treated with megavoltage irradiation using
parallel opposed fields, and great care was
taken to obtain accurate dosimetry. All
patients had their treatment fields simulated
and C.T. scans were taken through the centre
ofthe fields in order to measure the thickness
oflung in each field. From this the mid-plane
dose was calculated for each field, correcting
for increased lung transmission.
Misonidazole.-The lesions designated as
controls were irradiated first, and the lesions
to be treated with the sensitizer were irra-
diated later the sameday, 4 h after thepatient
had received MIS. The blood level of MIS
was measured in all cases at the time of
irradiation.
Tumour voluvie quantitation.-After treat-
ment to the metastases. patients were fol-
]owed up at regular intervals and assessed bv
the same observer. In order to minimize
observer error, neither the results of earlier
measurements nor the key indicating ANhich
treatment had been received by each lesion
",as available to the observer. Data analysis
and construction of growth curves for
pulmonary metastases Avere also donewithout
knowledge of the ti-eatment received.
Subcutaneous lesions were measured along
their maximum and minimum diameters and
the mean obtained. It ANas assumed that the
lesions were spheroidal, and the mean dia-
meter was used to convert to a volume
measurement.
Pulmonary metastases Avere followed by
regular chest X-rays, all of which were per-
formed under standard conditions of magni-
fication and exposure. The metastases were
measured by tracing their outline on paper
and measuring the area using millimetre-
squared graph paper. Care Avas taken to
follow solitary rounded metastases which
AA,ere assumed to be spheroidal, so that areas
could be converted to volumes. 'fn order to
compare directly the regression and regrowth
of lesions of initially different sizes, the
measurements of lung and subcutaneous
metastases AN-ere normalized to I-0 at the time
ofradiation and fractional changes in volume
plottedagainst time.
Enhance)nent ratio (ER)
This was defined as the ratio of radiation
doses with and without MIS that produced
equal effects on the tumour. The end-point
for judging tumour response was the time
taken for the tumour to regroxi, to its volume
at the time of irradiation (growth delay).
In this study single and fractionated doses
were selected so that the observation ofequal
growth delay with and without sensitizer
would indicate ER values of 1-2 to 1-5.
In situations NN-here the growth delay for the
sensitizer-radiation-treated tumour was
greater than for the radiation-treated tumour.
ER could not be calculated although clearly
it was greater tiian the expected value.
Details of the 6 patients in whom tumour
regression and regrowtb were documented
are summarized in the Table, and further
briefclinical data given in Figs 1-6.
RESULTS
Of the 6 sets of observations, evidence
of an enhanced anti-tumour effect with
the MIS-radiation combination was ob-TUMOUR RESPONSE TO RADIATION AND MISONIDAZOLE 885
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FIG. I.-Case 2. Female age(I 16. Osteosar-
coma ith lung metastases in sp'te of
intensix-e adjuvant chemotherapy.
No treatment (appeare(i at 10
days)
A..A 960 rad before AITS
800 rad 4 h after AIIS (5 g=
3-4 g/M2)
Growth curves sliow that growti-i delay for
800 ra(l is at least as long as that for 900
rad (ER 1-2)
tained in 5 patients. In I this could not be
quantified, and was based on differential
clearance of ulcerating tumour from skin
irradiated before or after MIS. Four ofthe
5 patients with growth-delay data showed
ERs from 1-1 to > 1-5. This included one
patient receiving a 10-fraction course of
radiation producing an ER of 1-3. In the
6th patient there was no evidence of
sensitization with a dose of 500 rad, and
observation was too brief to allow re-
growth after 900 rad.
Dose-response data wereobtainablefrom
4 cases. Three of these showed that incre-
ments in dose increased growth delay, and
that differences in dose of 200 rad were
distinguishable.
Toxicity
There was no evidence of MIS toxicity
in the study.
There has been no evidence of an in-
crease in normal-tissue reactions in the
areas irradiated afterMIS, as measured by
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FiG. 2.-Ccise 3. Female age(i 81. Leiomyo-
sareomawitli subeutaneousdeposits. Radia-
tion given for relief of local symptoms.
400 rad 4 h after MIS (5 g
3-3 g/M2)
600 rad before MIS
500 rad 4 li after MIS
Growth curves show little difference be-
tween growth delay for 600 rad before and
400 rad after MTS (ER > 1-5). 500 rad after
AITS produced a mucli greater effect.
skin pigmentation at Day 40 (Dische &
Zanelli, 1976). The observed pulmonary
reactions were consistent with the radia-
tion doses used, and there was no obvious
enhancement ofresponse.
DISCUSSION
Growth-delay studies in man are diffi-
cult, but it is nevertheless important to
attempt this approach, since evidence of
radiosensitization in clinical therapeutic
studies is likely to be amassed slowly from
controlled trials over a period of years.
Tf more than qualitative data are to be
obtained from this type ofstudy, however,
the most important feature of the growth-
delay-measurement system is that it
should distinguish between the effects of
different doses of radiation. In this way
the sensitivity of the system may beI
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FIG. 3.-Case 4. Female aged 47. Squamous
carcinoma ofpinna with extensive bilateral
pulmonary metastases. Lung fields were
divided into 4 quadrants, 2 of which were
treated before MIS and 2 after. All fields
received a 10-fraction course of irradiation
over 2 weeks. The 2 right-side quadrants,
A & B, were treated in the first 2 weeks,
each treatment 4 h after MIS (1-2 g/M2;
mean blood level 26 iLg/ml).
A 168 rad x 10+MIS
B 140 rad x 10+MIS
After a rest of one week the left side, C & D,
was treated without MIS.
...... C 182 rad x 10
D 168 rad x 10
No regression of left-side metastases was
notedwhileexposed to MIS aloneduring the
first 2 weeks.
All deposits regressed after treatment;
some disappeared and some became fluffy
and unmeasurable. Only 2-4 deposits were
measurableaccuratelyduringregressionand
regrowth in eachfield, and thegrowth curve
represents the mean volume of deposit
measured in each field.
Though fields A and D eachreceived 10 x
168 rad, growth delay for A irradiated
with MIS islarger than for D. Growth delay
for A (IO x 168 rad+MIS) is also greater
than for C (10 x 182 rad alone) suggesting
ER > I
-1. Growth delay for B (I0 x 140
rad+MIS) is very similar to C (10 x 182
rad alone) suggesting ER= 1-3.
established. In this study evidence of dose
response was obtained in 4 patients but
was contradictory in Case 5, where 600 rad
gave a greater growth delay than 700 rad.
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FiG. 4.-Ca8e 4. Growth delay ofindividual
lung metastases in each fieldplottedagainst
radiation dose
9 With MIS
Fj Without MIS
Larger growth delay with smaller radiation
doses when treated with MIS.
The dose-response data in Case 3 were
unusual in demonstrating a large differ-
ence between 400 and 500 rad after MIS.
The other 2 cases, however, appear to
resolve differences of 200 rad between
treatments, and indicate that it ispossible
to use the method for such comparison.
Inpreviouslyreported studies ofMIS in
man, large single doses of radiation (800-
1200 rad) have been used (Thomlinson et
al., 1976; Dische et al., 1976). In the pre-
sent series ofpatients Case 2 received only
400-500 rad and Case 4 600-700 radsingle
doses after MIS and both showed evidence
of enhancement of effect. Case 4 received
only 140-168 rad at each fraction, yet
evidence ofenhancement wasagain found.
The fact that any effect at all was found
when suchrelatively low doses ofradiation
were given is encouraging, and suggests
that the proportion of hypoxic cells in
these human tumours may be higher than
thatpostulatedbyDenekamp et al. (I977).
These observations also suggest that it888 D. V. ASH, M. J. PECKHAM AND G. G. STEEL
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Fie.. 5.-Case 5. Male aged 67. Advanced
adenocareinoma of prostate with deposits
in right and left axillary nodes plus sub-
cutaneous lesions in right supraclavicular
fossa (sef) and on chin. Left and right
axillary nodes received 800 and 900 rad
before MIS, and right scf and chin de-
posits received 600 and 700 rad 4 h after 6 g
MIS
0..e 600 rad after MIS
A A 700 rad after MIS
F-I F-1 900 rad before MIS
All treated lesions regressed, but it became
impossible to measure left axillary node
accurately, and considerable scatter was
also seen on right axillary node. Growth
curves sliow that after MIS 600 rad pro-
ducedlongergrowthdelay than 700rad, but
that 900 rad before MIS appeared to pro-
duce a shorter growth delay than either
600 or 700 rad.
may not be necessary to uselarge fractions
ofirradiation to achieve radiosensitization
in man.
Other animal experiments have shown
that when radiosensitizers are given with
fractionated radiation, the sensitizing en-
hancement ratio falls considerably (Hill &
Bush, 1978). This has led to the postulate
that re-oxygenation occurred between
radiation treatments, thus reducing the
number ofhypoxic cells. The majority of
these experiments have, however, used
animal tumours thatre-oxygenaterapidly.
When the sameexperiments wererepeated
with a tumour that re-oxygenates poorly
(Sheldon & Fowler, 1978) sensitization
was observed even when 20 or 30 fractions
of radiation had been given. The time
course and degree of re-oxygenation in
human tumours is notknown, and islikely
to vary between tumours. The fact that
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Fia. 6.-Male aged 26. Extensive lung meta-
stases from a primary synoviosarcoma of
left shoulder that had failed to respond to
cytotoxic chemotlierapy.
500 rad 4 h after 7 g MIS (4g/M2)
900 rad after MIS
F. F-I 700 rad before MIS
A -A 900 rad before MIS
Growth curves show no evidence of sensi-
tization when 500 rad+MIS compared
with 700 rad without. Observation period
too short to assess effect of 900 rad.
Case 4 showed evidence of radiosensitiza-
tion with a 10-fraction radiation regime
would support the beliefthat there was an
appreciable hypoxic cell component in
lung metastases and that re-oxygenation,
if it occurred, was incomplete. Similar
conclusions may be drawn from the
M.R.C. Hyperbaric Oxygen Trial for
carcinoma of the cervix (Watson et al.,
1978), which showed a benefit for hyper-
baricO2 even in patients treated with 30
fractions of radiation. The evidence en-
courages the study of MIS with multi-
fraction regimes in other human tumours.
The use ofinternal controls in sen.8''itizer
studies means that all metastatic tumouris
exposed to MIS, with some tumour irradi-
ated before and some after the drug.
Experimental work has shown, both in
vitro (Stratford & Adams, 1978) and in
vivo (Brown et al., 1978; Pedersen et al.,
1978), that MIS can be directly cytotoxic
to hypoxic cells. It is unlikely that this is
relevant to the present type of study,
although the long half-life of the drug in
man would allow considerable exposure to
thiscytotoxic effect.Denekamp &McNally
(1978) have suggested that ifthe enhance-TUMOUR RESPONSE TO RADIATION AND MISONIDAZOLE 889
ment seen in lesions irradiated after MIS
is an effect over and above that which has
produced cytotoxicity in the control
lesions, the role ofcytotoxicity is likely to
be small, otherwise the enhancement due
to radiosensitization would not be evident.
In the I patient in whom lung metastases
were exposed to MIS alone, no measurable
volume change was detected, though it is
unlikely that anyhypoxic cellcytotoxicity
would be detectable in this way.
One of the important future questions
about clinical application of radiosensi-
tizers concerns the types of tumour in
whichthey arelikely to be of most benefit.
The 5 cases with evidence of radiosensi-
tization in thisstudy comprise 2 sarcomas,
2 adenocareinomas and a squamous-cell
carcinoma, suggesting that the spectrum
of effectiveness may well cover a wide
range of human tumours. More extensive
data are required to identify those cate-
gories of disease that will respond best to
treatment with radiosensitizers.
Analysis ofdata for Case 4 wasperformed with the
valuable assistance of M'ss D. Markham.
Misonidazole was supplied by Roebe Products
Ltd., Welwyn Garden City, Herts.
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